🔴 Sanofi is trading 7.1% down today on strategy shift and pipeline cuts

Sanofi is trading 7.1% down at $41.82 following the release of its Q2 2026 results and a significant update to its corporate strategy.

• While the company beat revenue and earnings expectations and raised its full-year guidance, investors are reacting to the new CEO’s focus on portfolio reshaping and pipeline cuts.
• Strong performance from the blockbuster drug Dupixent was overshadowed by market concerns regarding future growth prospects under the revised strategic direction.
• The sell-off reflects skepticism over the long-term impact of the company's aggressive restructuring despite the positive quarterly financial performance.